Our findings support a “licensing” role of Blnc1 and its protein partners in obesity-linked activation of hepatic lipogenesis and NAFLD pathogenesis (Fig. 10d). The gene discussed is PAQR9; the disease is metabolic dysfunction-associated steatotic liver disease.